Skip to main content
×
Home
    • Aa
    • Aa
  • Access
  • Cited by 2
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Enwonwu, C.O. 2009. Food Constituents and Oral Health.


    Löbbe, Velia A 2009. Nutrition in the last days of life. Current Opinion in Supportive and Palliative Care, Vol. 3, Issue. 3, p. 195.


    ×
  • Proceedings of the Nutrition Society, Volume 66, Issue 4
  • November 2007, pp. 483-492

Risk management of nutritional supplements in chronic illness: the implications for the care of cancer and depression

  • Ursula Werneke (a1)
  • DOI: http://dx.doi.org/10.1017/S0029665107005800
  • Published online: 25 October 2007
Abstract

The use of complementary medicines in patients suffering from chronic illnesses such as cancer and depression is widely documented. Current studies suggest that the prevalence of the use of complementary medicines in patients with cancer ranges from 7% to 80%. In patients suffering from severe depression the use of complementary medicines may be >40%. The aim of the present review is to systematically explore the main dimensions that clinicians have to consider when advising patients suffering from these conditions. The Medline and Cochrane databases were searched for evidence relating to the benefits and risks of supplements in the treatment of cancer and depression, including the potential interactions with pharmaco- and radiotherapy. Supplements predominantly used by patients with cancer include vitamins A, C and E, β-carotene and ubiquinone 10. Supplements predominantly used by patients with depression include S-adenosylmethionine, l-tryptophan and 5-hydroxytryptophan and inositol. Supplements potentially used by both groups include n-3 fatty acids, Se and folic acid. Four dimensions are identified and discussed: effectiveness; safety; communication; medico-legal aspects. These dimensions have to be addressed in an illness- and case-specific context. This task can be complex given the emerging clinical evidence, patients' own preferences and expectations and current prescribing guidelines.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Risk management of nutritional supplements in chronic illness: the implications for the care of cancer and depression
      Your Kindle email address
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Risk management of nutritional supplements in chronic illness: the implications for the care of cancer and depression
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Risk management of nutritional supplements in chronic illness: the implications for the care of cancer and depression
      Available formats
      ×
Copyright
Corresponding author
Corresponding author: Dr Ursula Werneke, fax +46 11 223926, email uwerneke@easynet.co.uk
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.DM Eisenberg , RC Kessler , C Foster , FE Norlock , DR Calkins & TL Delbanco (1993) Unconventional medicine in the United States. Prevalence, costs and pattern of use. N Engl J Med 328, 246252.

2.E Ernst & BR Cassileth (1999) How useful are unconventional cancer treatments? Eur J Cancer 35, 16081613.

4.U Werneke , T Turner & S Priebe (2006) Complementary alternative medicine in psychiatry: a review of effectiveness and safety. Br J Psych 188, 109121.

6.J Unutzer , R Klap , R Sturm , AS Young , T Marmon , J Shatkin & KB Wells (2000) Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry 157, 18511857.

12.EN Drake (2006) Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med Hypotheses 67, 318322.

15.EH Turner & AD Blackwell (2005) 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypothesis 65, 138144.

16.K Shaw , J Turner & C Del Mar (2002) Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Aust N Z J Psychiatry 36, 488491.

18.M Morris , M Fava & PF Jaques (2003) Depression and folate status in the US population. Psychothep Psychosom 72, 8087.

19.G Schreiber & S Avissar (2005) Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action. Expert Rev Neurother 7, 7584.

20.CG Hahn , Umapathy , HY Wang , R Koneru , DF Levinson & E Friedman (2005) Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res 39, 355363.

23.MJ Taylor , S Carney , J Geddes & G Goodwin (2003) Folate for depressive disorders. Cochrane Database of Systematic Reviews, issue 2, art no. CD003390. Chichester, West Sussex: John Wiley & Sons Ltd.

24.B Hallahan & MR Garland (2005) Essential fatty acids and mental health. Br J Psychiatry 186, 275277.

25.MP Freeman , JR Hibbeln , KL Wisner (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67, 19541967.

27.SM Dursun , JR Blackburn & SP Kutcher (2001) An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap. Med Hypothesis 56, 235243.

28.L Cheng , M Lumb , L Polgar & AW Mudge (2005) How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 29, 155161.

30.J Levine (1997) Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 7, 147155.

31.AA Nierenberg , MJ Ostacher , JR Calabrese (2006) Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 163, 210216.

32.A Eden Evins , C Demopulos , I Yovel , M Culhane , J Ogutha , LD Grandin , AA Nierenberg & GS Sachs (2006) Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 8, 168174.

34.A Castano , A Ayala , JA Rodriguez-Gomez , AJ Herrera , J Cano & A Machado (1997) Low selenium diet increases the dopamine turnover in prefrontal cortex of the rat. Neurochem Int 30, 549555.

35.WC Hawkes & L Hornbostel (1996) Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry 39, 121128.

38.KM Hayden , KA Welsh-Bohmer , HJ Wengreen , P Zandi , C Lyketsos & J Breitner (2007) Risk of mortality with vitamin E supplements: the Cache County study. Am J Med 120, 180184.

41.PC Dagnelie , AG Schuurman , RA Goldbohm & PA Van den Brandt (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93, 11391150.

44.U Werneke , J Earl , C Seydel , O Horn , P Crichton & D Fannon (2004) Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90, 408413.

47.HE Bays (2006) Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 99, 35C43C.

49.TJ Simat , KK Kleeberg , B Muller & A Sierts (1999) Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 467, 469480.

55.GM D'Andrea (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55, 319321.

57.AL Stoll , WE Severus , MP Freeman , S Rueter , HA Zboyan , E Diamond , KK Cress & LB Marangell (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56, 407412.

58.WS Harris (2007) Expert opinion: omega-3 fatty acids and bleeding – cause for concern? Am J Cardiol 99, 44C46C.

59.EM McClaskey & E Michalets (2007) Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy 27, 152160.

63.SM Bryant & J Kolodchak (2004) Serotonin syndrome resulting from a herbal detox cocktail. Am J Emerg Med 22, 625626.

64.HA Friedel , KL Goa & P Benfield (1989) S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 38, 389416.

73.G Bjelakovic , D Nikolova , RG Simonetti & C Gluud (2004) Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 364, 12191228.

74.G Lodi , A Sardella , C Bez , F Demarosi & A Carrassi (2006) Interventions for treating oral leukoplakia. Cochrane Database of Systematic Reviews, issue 4, art. no. CD001829. Chichester, West Sussex: John Wiley & Sons Ltd.

84.MC Nollevaux , Y Guiot , Y Horsmans , I Leclercq , J Rahier , AP Geubel & C Sempoux (2006) Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption. Liver Int 26, 182186.

85.WC Maddrey (2005) Drug-induced hepatotoxicity. J Clin Gastroenterol 39, Suppl. 2, S83S89.

87.DI Friedman (2005) Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 6, 2937.

88.FW Fraunfelder & FT Fraunfelder (2004) Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol 24, 214216.

90.M Fakih , S Cao , FA Durrani & YM Rustum (2005) Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer 5, 132135.

91.RG Azrak , S Cao , L Pendyala , F Durrani , M Fakih , G Combs , J Prey , P Smith & Y Rustum (2007) Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochem Pharmacol 73, 12801287.

93.J Kohrle (2005) Selenium and the control of thyroid hormone metabolism. Thyroid 15, 841853.

95.A Pace , A Savarese , M Picardo (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21, 927931.

101.H Koller , C Luley , B Klein , H Baum & HK Biesalski (1989) Contaminating substances in 22 over-the-counter fish oil and cod liver oil preparations: cholesterol, heavy metals and vitamin A. Z Ernahrungswiss 28, 7683.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Proceedings of the Nutrition Society
  • ISSN: 0029-6651
  • EISSN: 1475-2719
  • URL: /core/journals/proceedings-of-the-nutrition-society
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: